Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. by Di Tanna, Gian Luca et al.
LSHTM Research Online
Di Tanna, Gian Luca; Khaki, Ali Raza; Theron, Grant; McCarthy, Kerrigan; Cox, Helen; Mup-
fumi, Lucy; Trajman, Anete; Zĳenah, Lynn Sodai; Mason, Peter; Durovni, Retina; +14 more...
Bara, Wilbert; Hoelscher, Michael; Clowes, Petra; Mangu, Chacha; Chanda, Duncan; Pym, Alexan-
der; Mwaba, Peter; Cobelens, Frank; Nicol, Mark P; Dheda, Keertan; Churchyard, Gavin; Fielding,
Katherine; Metcalfe, John Z; Bandason, Tsitsi; (2019) Effect of Xpert MTB/RIF on clinical outcomes
in routine care settings: individual patient data meta-analysis. LANCET GLOBAL HEALTH, 7 (2).
E191-E199. ISSN 2214-109X DOI: https://doi.org/10.1016/S2214-109X(18)30458-3
Downloaded from: http://researchonline.lshtm.ac.uk/4654044/
DOI: https://doi.org/10.1016/S2214-109X(18)30458-3
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
www.thelancet.com/lancetgh   Vol 7   February 2019 e191
Lancet Glob Health 2019; 
7: e191–99
This online publication has 
been corrected. The corrected 
version first appeared at 
thelancet.com/lancetgh on 
February 19, 2019 
See Comment page e161
TB Centre (G L Di Tanna PhD, 
K Fielding PhD), London School 
of Hygiene and Tropical 
Medicine, London, UK 
(Prof K Dheda PhD); 
Riskcenter-IREA, Department 
of Econometrics, Statistics and 
Applied Economics, University 
of Barcelona, Barcelona, Spain 
(G L Di Tanna); Division of 
Oncology, University of 
Washington, Seattle, WA, USA 
(A R Khaki MD); DST-NRF Centre 
of Excellence for Biomedical 
Tuberculosis Research and 
SAMRC Centre for Tuberculosis 
Research, Division of Molecular 
Biology and Human Genetics, 
Faculty of Medicine and Health 
Sciences, Stellenbosch 
University, Tygerberg, South 
Africa (G Theron PhD); National 
Institute for Communicable 
Diseases, National Health 
Laboratory Service, 
Johannesburg, South Africa 
(K McCarthy MBBCh, 
M P Nicol PhD); Division of 
Medical Microbiology, and 
Institute of Infectious Disease 
and Molecular Medicine, 
University of Cape Town, Cape 
Town, South Africa (H Cox PhD, 
M P Nicol); Botswana Harvard 
AIDS Institute, Gaborone, 
Botswana (L Mupfumi MPH); 
Federal University of Rio de 
Janeiro, Rio de Janeiro, Brazil 
(A Trajman MD); McGill 
University, Montreal, QC, 
Canada (A Trajman); 
Department of Immunology, 
University of Zimbabwe 
College of Health Sciences, 
Harare, Zimbabwe 
(L S Zijenah PhD); Biomedical 
Research and Training 
Institute, Harare, Zimbabwe 
(P Mason PhD; T Bandason PhD); 
Municipal Health Secretariat, 
Rio de Janeiro, Brazil 
Articles
Effect of Xpert MTB/RIF on clinical outcomes in routine care 
settings: individual patient data meta-analysis
Gian Luca Di Tanna, Ali Raza Khaki, Grant Theron, Kerrigan McCarthy, Helen Cox, Lucy Mupfumi, Anete Trajman, Lynn Sodai Zijenah, 
Peter Mason*, Tsitsi Bandason, Betina Durovni, Wilbert Bara, Michael Hoelscher, Petra Clowes, Chacha Mangu, Duncan Chanda, Alexander Pym, 
Peter Mwaba, Frank Cobelens, Mark P Nicol, Keertan Dheda, Gavin Churchyard, Katherine Fielding, John Z Metcalfe
Summary
Background Xpert MTB/RIF, the most widely used automated nucleic acid amplification test for tuberculosis, is 
available in more than 130 countries. Although diagnostic accuracy is well documented, anticipated improvements in 
patient outcomes have not been clearly identified. We performed an individual patient data meta-analysis to examine 
improvements in patient outcomes associated with Xpert MTB/RIF. 
Methods We searched PubMed, Embase, ClinicalTrials.gov, and the Pan African Clinical Trials Registry from inception to 
Feb 1, 2018, for randomised controlled trials (RCTs) comparing the use of Xpert MTB/RIF with sputum smear microscopy 
as tests for tuberculosis diagnosis in adults (aged 18 years or older). We excluded studies of patients with extrapulmonary 
tuberculosis, and studies in which mortality was not assessed. We used a two-stage approach for our primary analysis 
and a one-stage approach for the sensitivity analysis. To assess the primary outcome of cumulative 6-month all-cause 
mortality, we first performed logistic regression models (random effects for cluster randomised trials, with robust SEs for 
multicentre studies) for each trial, and then pooled the odds ratio (OR) estimates by a fixed-effects (inverse variance) or 
random-effects (Der Simonian Laird) meta-analysis. We adjusted for age and gender, and stratified by HIV status and 
previous tuberculosis-treatment history. The study protocol has been registered with PROSPERO, number 
CRD42014013394.
Findings Our search identified 387 studies, of which five RCTs were eligible for analysis. 8567 adult clinic attendees 
(4490 [63·5%] of 7074 participants for whom data were available were HIV-positive) were tested for tuberculosis with 
Xpert MTB/RIF (Xpert group) versus sputum smear microscopy (sputum smear group), across five low-income and 
middle-income countries (South Africa, Brazil, Zimbabwe, Zambia, and Tanzania). The primary outcome (reported 
in three studies) occurred in 182 (4·5%) of 4050 patients in the Xpert group and 217 (5·3%) of 4093 patients in the 
smear group (pooled adjusted OR 0·88, 95% CI 0·68–1·14 [p=0·34]; for HIV-positive individuals OR 0·83, 0·65–1·05 
[p=0·12]). Kaplan-Meier estimates showed a lower rate of death (12·73 per 100 person-years in the Xpert group vs 
16·38 per 100 person-years in the sputum smear group) for HIV-positive patients (hazard ratio 0·76, 95% CI 
0·60–0·97; p=0·03). The risk of bias was assessed as reasonable and the statistical heterogeneity across studies was 
low (I²<20% for the primary outcome).
Interpretation Despite individual patient data analysis from five RCTs, we were unable to confidently rule in nor rule 
out an Xpert MTB/RIF-associated reduction in mortality among outpatients tested for tuberculosis. Reduction in 
mortality among HIV-positive patients in a secondary analysis suggests the possibility of population-level impact.
Funding US National Institutes of Health.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license. 
Introduction
Tuberculosis is the leading global cause of death due to 
an infectious disease. Inadequate case detection is a 
major barrier to current tuberculosis control efforts, 
contributing to the 36% of the estimated 10 million 
cases in 2017 not notified to tuberculosis programmes.1 
The poor sensitivity of sputum smear microscopy for 
the detection of acid-fast bacilli coupled with the 
laboratory infrastructure necessary for Mycobacterium 
tuberculosis culture provide strong impetus for the 
development of new, programme-relevant tuberculosis 
diagnostic tools.
The introduction of an automated nucleic acid 
amplification test (NAAT),2 the GeneXpert MTB/RIF assay 
(also known as Xpert MTB/RIF; Cepheid, Sunnyvale, CA, 
USA) in December, 2010, was a groundbreaking advance 
in tuberculosis diagnostics. Relative to the conventional 
standard (ie, sputum smear microscopy), Xpert MTB/RIF 
offers improved analytic sensitivity and high specificity for 
individuals not previously treated for tuberculosis, and 
allows for drug susceptibility testing for rifampicin 
resistance with an on-demand (ie, random access, without 
need for batching) quality-controlled system requiring 
only minimal laboratory technician training. However, 
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international scale-up and optimal programmatic use of 
Xpert MTB/RIF has been delayed by high product 
costs, inadequate service and maintenance plans, inability 
to use the platform within most microscopy centres, and 
lack of attention to dedicated implementation strategies.3–5 
Further more, despite the success of demon stration 
studies6,7 and early cost-effectiveness models adopting 
treatment benefits derived from observational studies,8,9 
evidence for improved morbidity and mortality with Xpert 
MTB/RIF has thus far not been supported by high-quality 
studies.
As in randomised controlled trials (RCTs) of tuber cu-
losis therapeutics,10 surrogate markers for patient-
important outcomes for diagnostic-test evaluation—such 
as test accuracy, turnaround time, time to diagnosis, and 
time to treatment—might not translate onward to clinical 
outcomes and could be subject to substantial hetero- 
geneity.11 Although therapeutic outcomes are similarly of 
primary interest in diagnostic RCTs,12,13 they have received 
less methodological attention than tuberculosis thera-
peutic trials.14 Five diagnostic RCTs15–19 across 41 sites in 
South Africa, Brazil, Zimbabwe, Zambia, and Tanzania, 
assessing the effect of Xpert among people tested 
for tuberculosis in routine-care settings have been 
done. Along with consistent increases in the proportion 
of bacteriologically con firmed cases, the possibility of 
decreased early mortality at 2 months15 and 3 months16 
has been raised, although estimates have been imprecise. 
Overall, high rates of empirical tuberculosis treatment, a 
relatively low-risk target population (eg, outpatients), and 
type 2 error (ie, insufficient power) have been most 
commonly used to explain the absence of effect on 
morbidity or mortality.20
We did a systematic review and an individual patient 
data (IPD) meta-analysis to examine whether use of Xpert 
MTB/RIF as a replacement for conventional sputum 
smear microscopy improves patient-centred outcomes 
such as mortality and time to tuberculosis diagnosis and 
treatment. Furthermore, we assessed the possibility of 
differential effects across prespecified patient subgroups, 
including HIV-positive individuals and those with a 
previous history of tuberculosis treatment.
Methods
Search strategy and selection criteria
For this systematic review and meta-analysis we search ed 
PubMed, Embase, ClinicalTrials.gov, and the Pan African 
Clinical Trials Registry from inception to Feb 1, 2018, 
for RCTs in English; we also contacted experts in 
the field to identify ongoing and completed trials. A 
search strategy was developed in consultation with an 
information specialist (librarian) who has extensive 
experience in systematic reviews. Search terms included 
a combination of free text and controlled vocabulary 
(ie, Medical Subject Headings terms): ((tuberculosis 
AND (mtb/rif OR xpert OR genexpert OR cepheid OR 
NAAT OR NAA test* OR nucleic acid amplification 
test*)) OR (tuberculosis[mh] AND “nucleic acid 
amplification techniques”[mh])) AND (“randomized 
controlled trial”[pt] OR random* OR “controlled 
trial”). Additional terms included: “tuberculosis”, “MTB/
RIF”, “Xpert”, “GeneXpert”, “Cepheid”, “nucleic acid 
amplification test”, “NAAT”, and “randomized 
controlled trial”. We excluded studies that were not 
RCTs; did not use Xpert or sputum smear microscopy; 
included children, patients with extrapulmonary 
tuberculosis, or patients not tested for tuberculosis; did 
not compare Xpert and sputum smear microscopy; did 
not assess mortality. ARK and JZM did the search and 
ARK and GLDT extracted data. We used IPD for 
Research in context
Evidence before this study
Relative to acid-fast bacilli sputum smear microscopy, the first 
Mycobacterium tuberculosis-specific automated nucleic acid 
amplification test—GeneXpert MTB/RIF (Xpert MTB/RIF)—has 
shown improvement in several key surrogate patient 
outcomes, such as analytical sensitivity, test turnaround time, 
time to treatment initiation, and increase in proportion of 
bacteriologically confirmed cases. However, randomised 
controlled trials among clinic attendees tested for tuberculosis 
in routine-care settings, the endpoints of which have included 
morbidity and mortality, have produced inconclusive results. 
We hypothesised that pooling these trials in an individual 
patient data meta-analysis would provide increased power in 
determining whether Xpert MTB/RIF does confer such 
downstream benefits.
Added value of this study
By pooling patient-level data from five diagnostic randomised 
controlled trials (n=8567 patients) in 41 sites in South Africa, 
Brazil, Zimbabwe, Zambia, and Tanzania, we found that use of 
Xpert MTB/RIF was not associated with decreased time to either 
tuberculosis diagnosis or commencement of tuberculosis 
treatment, and did not decisively reduce overall 6-month all-cause 
mortality among outpatients investigated for tuberculosis, 
relative to smear microscopy; our results are consistent with a 
possible mortality reduction of up to 32% and a mortality increase 
of up to 14%, with the best estimate being a 12% reduction. There 
was modest evidence for a decrease in HIV-specific mortality.
Implications of all the available evidence
We were unable to conclusively show Xpert MTB/RIF-associated 
reduction in mortality among clinic attendees tested for 
tuberculosis relative to sputum smear microscopy. There 
remains uncertainty on this question, in particular around a 
potential mortality benefit among HIV-positive individuals or 
other high-risk groups. The impact of novel diagnostics on 
overall mortality is likely to remain attenuated in the context of 
sustained health system weaknesses.
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participants aged 18 years and older from randomised 
trials that, to our knowledge, represented the totality of 
evidence from RCTs evaluating the effect of Xpert MTB/
RIF versus sputum smear microscopy on patient 
outcomes among outpatients tested for tuberculosis.
Data analysis
Data were extracted for age, gender, HIV, history of 
tuberculosis, clinical symptoms, and body-mass index 
(BMI) or weight, where BMI was not available. Data were 
quality checked for each individual trial (all potential 
duplicates and missing data were assessed with the trial 
contributors) and then assembled to constitute a master 
data file.
Our primary outcome was cumulative risk (expressed 
as odds ratio [OR]) of all-cause mortality at 6 months 
following random assignment to groups of clinic 
attendees tested for tuberculosis with Xpert MTB/RIF 
(Xpert group) versus sputum-smear microscopy (sputum-
smear group). Secondary outcomes were time to death, 
time to tuberculosis diagnosis (ie, time from specimen 
collection to result available in the laboratory, if 
bacteriologically confirmed), time to tuberculosis treat-
ment (bacteriologically or clinically confirmed), and 
3-month cumulative mortality risk. We calculated the 
hazard ratio (HR) for time-to-event analyses and the OR 
for the 3-month mortality risk. Separately, among clinic 
attendees investigated for tuberculosis who started 
receiving tuberculosis treatment, we analysed time to 
death while on treatment. We prespecified stratified 
analyses for each outcome by HIV status and by history of 
previous tuberculosis treatment. Outcomes for which 
each study contributed data are summarised in the 
appendix. Risk of bias was assessed using the Cochrane 
Risk of Bias tool by two authors (ARK and JZM).
We did IPD meta-analysis using both one-stage and 
two-stage approaches.21 We report our primary analysis 
using the two-stage approach, and a sensitivity analysis 
using the one-stage approach. In the two-stage approach, 
for the binary outcomes (all-cause mortality at 3 months 
and 6 months), we fitted a logistic regression model 
for each study. Robust SEs were calculated for any 
multicentre study and a random-effects (at cluster level) 
logistic model was used for cluster-randomised trials. 
Pooled estimates were then obtained by fixed-effects 
(inverse variance) or random-effects (Der Simonian 
Laird) meta-analysis; we reported the results of random-
effects meta-analysis when statistical heterogeneity, 
assessed through a formal test of homogeneity and I², 
was large (approximately >60%). For time-to-event out-
comes, we used proportional-hazards Cox models, with 
robust SEs for multicentre studies and a shared frailty 
(random effect for cluster) for cluster-randomised trials. 
For stepped-wedge trials, we used a random-effects 
(laboratory-level) Cox model with a fixed effect for a 
covariate set including the timepoints at which Xpert 
MTB/RIF was introduced. All analyses were adjusted for 
age and gender; estimates of the pooled-intervention 
effect were further adjusted for weight (as a proxy 
for BMI) and number of tuberculosis symptoms (as a 
categorical variable), when possible. In the one-stage 
approach, we combined all IPD in a single meta-analysis,22 
with a hierarchical logistic regression allowing for study 
and cluster (if relevant) random effects for the binary 
outcomes. Cox models were fitted with shared frailties at 
study level and cluster level (if relevant) for time-to-event 
outcomes. For time-to-tuberculosis diag nosis, a follow-up 
time of 0·5 days was assumed for patients diagnosed on 
the same day as sputum collection. Only specimens taken 
at enrolment were used to define the time-to-tuberculosis 
diagnosis outcome. Data management and statistical 
analyses were done with Stata 14.
We prespecified our analytical plan in accordance with 
international recommendations23 and registered the study 
protocol with PROSPERO (CRD42014013394).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Our database search identified 387 potentially eligible 
studies. After the exclusion of 14 duplicates, of 353 studies 
after title and abstract screening, and of 15 studies after 
whole-text screening, we found five eligible RCTs 
comparing the use of Xpert MTB/RIF versus sputum 
smear microscopy for the diagnosis of tuberculosis 
(figure 1).15–19
All trials included participants aged 18 years or older. 
The XTEND study18 was a cluster-randomised trial 
randomly allocating 20 laboratories in medium-burden 
districts in four South African provinces (n=4656 patients) 
to assess 6-month mortality among clinic attendees being 
tested for tuberculosis. Using weeks randomly allocated 
to Xpert or sputum-smear groups, Cox and colleagues17 
analysed 1985 patients at a single primary health-care 
clinic in Khayelitsha, Cape Town, South Africa, and 
assessed the proportion of patients with bacteriologically 
confirmed tuberculosis who had not started receiving 
appropriate tuberculosis treatment within 2 months after 
enrolment. Mupfumi and coll eagues16 randomly assigned 
424 HIV-positive patients initiating antiretroviral therapy 
at a single centre in Harare, Zimbabwe, to be tested for 
tuberculosis with either Xpert MTB/RIF or sputum 
smear microscopy, and examined a composite endpoint 
of 3-month mortality and antiretroviral therapy-associated 
tubercu losis (ie, unmasking of subclinical tuberculosis 
disease). The TB-NEAT study15 randomly assigned to 
either Xpert or sputum-smear groups 1502 patients 
attending primary care clinics in South Africa, Tanzania, 
Zambia, and Zimbabwe who had at least one tuberculosis 
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symptom (two if HIV-negative) and were able to 
expectorate two sputum specimens; the primary 
outcome was tuberculosis-related morbidity at 2 months 
and 6 months. Durovni and colleagues19 did a stepped-
wedge cluster-randomised trial (CRT) in Rio de Janeiro 
and Manaus, Brazil, randomising the sequence of Xpert 
MTB/RIF introduction in 14 lab oratories (24 227 patients) 
and assessing the notification proportion of laboratory-
confirmed pulmonary tubercu losis. A second publi-
cation24 from the same research group reported mortality 
outcomes among patients who were initiated on 
tuberculosis treatment in the primary trial; these data 
contributed to the current analysis.
Our patient-level pooled analysis included data from 
8567 adult outpatients tested for tuberculosis. 
Participant characteristics, stratified by trial and ac - 
c ording to initial randomisation (ie, intention to treat), 
are shown in table 1. Overall HIV-positivity in these 
trials was 63·5% (4490 of the 7074 participants tested 
for HIV; ranging from 59%17 to 100%16); overall, 
54·5% (4665 of 8567) of participants were women and 
the median age was 37 years (IQR 29–47 years). Except 
for the inability to blind the intervention (for all trials), 
and lack of allocation concealment (for two trials),17,19 
risk of bias was assessed to be reasonable and the 
statistical heterogeneity across studies was generally 
low (I² <20% for the mortality outcomes; appendix). For 
the primary outcome of 6-month mortality risk among 
outpatients tested for tuberculosis, 399 (4·9%) primary 
endpoints among 8142 individuals (three studies; 
figure 1)15,17,18 contributed to the analysis. Overall all-
cause 6-month mortality occurred in 182 (4·5%) of 
4050 patients in the Xpert group and 217 (5·3%) of 
4093 patients in the sputum-smear group (pooled 
OR 0·88, 95% CI 0·68–1·14; p=0·34); stratified analysis 
showed a pooled OR of 0·83 (0·65–1·05; p=0·12) for 
HIV-positive individuals and 0·83 (0·46–1·5; p=0·55) 
for HIV-negative individuals. Analysis of 3-month 
mortality (four studies)15–18 and stratification by history 
of previous tuberculosis gave results similar to the 
overall estimate (table 2).
Time to death among clinic attendees investigated 
for tuberculosis included 425 (5·0%) events among 
8561 individuals (four studies)15–18 over 3983 person-years 
of follow-up. With time-to-event analysis, there were 
9·69 deaths per 100 person-years in the Xpert group and 
11·63 deaths per 100 person-years in the smear microscopy 
group (HR 0·83, 95% CI 0·65–1·06; p=0·13; figure 2). 
These results were similar in sensitivity analyses adjusting 
for age, gender, weight, and tuberculosis symptoms 
(6568 individuals from three studies;15,16,18 appendix). 
Among HIV-positive individuals, all-cause death in the 
Xpert group (12·73 per 100 person-years) was lower than 
in the sputum-smear group (16·38 per 100 person-years; 
HR 0·76, 0·60–0·97; p=0·03) as per the data from four 
studies (figure 2).15–18 The significance of this finding was 
maintained after further adjustment for age, gender, 
weight, and tuberculosis symptoms (appendix).
Across all trials, 6468 (19·7%; ranging from 
12%18 to 43%15) of 32 794 outpatients investigated for 
tuberculosis ultimately received tuberculosis treatment. 
Time to tuberculosis diagnosis did not differ for 
1924 individuals from two studies, with a median of 
0·5 days (IQR 0·5–10) for each group (pooled HR 1·05, 
95% CI 0·93–1·19; p=0·43).15,16 The median time to 
tuberculosis treatment for 8208 individuals from four 
studies15–18 was 4 days (1–10) for the Xpert group versus 
5 days (1–15) for the smear group (1·0, 0·75–1·32; 
p=0·99), although it was shorter for patients in the Xpert 
group reporting a history of previous tuberculosis 
Figure 1: Study selection
RCT=randomised controlled trial. *The primary outcome was limited to three 
studies15,17,18 (n=8142), as Mupfumi and colleagues16 limited follow-up to 3 months.
387 potentially eligible studies 
identified by database search
181 PubMed or MEDLINE
206 Embase
14 excluded (duplicates)
373 identified for screening
353 excluded after title and abstract 
screening
232 not an RCT
85 did not use Xpert
22 extrapulmonary 
tuberculosis
9 did not use sputum
5 paediatric population
15 excluded after full-text 
screening
5 multiple records on same 
dataset
3 different patient population 
(ie, not patients investigated
for tuberculosis)
3 mortality not assessed
3 not comparing Xpert vs 
sputum
1 not an RCT
20 screened by full text
5 eligible diagnostic RCTs
1 study only included treatment 
outcomes for clinic attendees 
starting tuberculosis treatment
4 studies of clinic attendees 
investigated for tuberculosis 
(8562 individuals) included 
in primary outcome* and 
secondary outcome analysis
5 studies of clinic attendees
who have started tuberculosis 
treatment (5797 individuals) 
included in post-
randomisation subgroup 
analysis
See Online for appendix
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treatment than for patients in the sputum-smear group 
(0·73, 95% CI 0·53–0·99; p=0·04). In a prespecified 
subgroup time-to-event analysis of 5797 adults who 
started receiving tuberculosis treatment (all trials),15–19 we 
found a possible 33% relative decrease in the rate of 
deaths in the Xpert group versus the sputum-smear 
group (0·67, 0·50–0·90; p=0·007). 6-month all-cause 
mortality was higher among individuals tested for 
tuberculosis but who ultimately did not start receiving 
treatment than among those initiating tuberculosis 
treatment (4·3% [133 of 3082] in the Xpert group vs 
6·7% [182/2715] in the sputum-smear group). In this 
group of individuals, the summary HR for death in the 
Xpert group versus sputum-smear group was 0·89 
(0·70–1·14; p=0·34) among all outpatients, and 0·84 
(0·67–1·05; p=0·12) among HIV-positive individuals.
Discussion
In an IPD meta-analysis of 8567 outpatients tested for 
tuberculosis in five low-income and middle-income 
countries, we were unable to rule in nor rule out a 
reduction in 6-month all-cause mortality associated with 
use of Xpert MTB/RIF as an initial diagnostic test, 
relative to sputum smear microscopy. Our results are 
consistent with a plausible reduction in mortality of up to 
32% and up to a 14% increase in mortality, with the 
Theron et al  
(2014)15
Mupfumi et al  
(2014)16
Cox et al  
(2014)17
Churchyard et al 
(2015)18
Durovni et al (2014)19 
and Trajman et al 
(2015)22
Trial characteristics
Type of trial RCT RCT CRT CRT SW
Comparative SOC* FM† FM FM FM ZN
Setting South Africa, Zimbabwe, 
Zambia, Tanzania
Harare (Zimbabwe) Khayelitsha (South Africa) South Africa Brazil
Adults investigated for tuberculosis
Analytic population, n 1502 424 1985 4656 NA
Xpert MTB/RIF group, n (%) 744 (50%) 214 (51%) 982 (50%) 2324 (50%) NA
Age (SD), years 39 (12) 38 (10) 41 (12) 38 (13) NA
Female, n (%) 643 (43%) 232 (55%) 900 (45%) 2890 (62%) NA
BMI (SD), kg/m² 21·9 (5·2) NR NR 25·5 (6·9) NA
Weight (SD), kg 59·7 (12·9) 59·7 (11·7) NR 65·1 (15·0) NA
Any tuberculosis symptoms, n (%) 1497 (99·9%) 388 (92%) NR 4382 (94%) NA
Mean number of tuberculosis symptoms (SD) 3·2 (0·9) 2·3 (1·3) NR 2·9 (1·3) NA
Prevalence of previous history of tuberculosis, n (%) 365 (24%) 52 (12%) NR 718 (15%) NA
HIV-positive individuals, n/N (%)‡ 895/1483 (60%) 424/424 (100%) 965/1625 (59%) 2206/3542 (62%) NA
Patients with CD4 ≥100 cells per µL, n/N (%)‡ 582/861 (68%) 272/420 (65%) NR 998/1130 (88%) NA
Overall trial mortality, n/N (%) 121/1502 (8%) 28/354 (8%)§ 71/1985 (4%) 207/4608 (5%)¶ NA
Adults investigated for tuberculosis and initiated on treatment
Population of adults on tuberculosis treatment n/N (%) 647/1502 (43%) 100/424 (24%) 540/1985 (27%) 541/4656 (12%) 4640/24 227 (19·2%)
Analytic population, n|| 647 84 506 520 4088
Xpert MTB/RIF group, n (%) 315 (49%) 41 (49%) 277 (55%) 240 (46%) 2232 (55%)
Age (SD), years 38·9 (11·8) 36·9 (9·7) 37·7 (10·1) 37·9 (11·8) **
Female, n (%) 289 (45%) 32 (38%) 306 (61%) 225 (43%) 1444 (35%)
BMI (SD), kg/m² 21·8 (5·2) NR NR 22·4 (5·5) NR
Weight (SD), kg 59·4 (13·0) 56·1 (9·3) NR 58·6 (11·3) NR
Any tuberculosis symptoms, n (%) 645 (100%) 84 (100%) NR 514 (99%) NR
Mean number of tuberculosis symptoms (SD) 3·1 (0·9) 3·1 (1·0) NR 3·4 (1·0) NR
Individuals with previous history of tuberculosis, n (%) 155 (24%) 11 (13%) NR 89 (17%) NR
HIV-positive individuals, n/N (%)‡ 402/639 (63%) 84/84 (100%) 298/506 (59%) 267/373 (72%) 399/2040 (20%) 
Patients with CD4 ≥100 cells per µL, n/N (%)‡ 262/376 (70%) 43/84 (51%) NR 90/116 (78%) NR
RCT=individually randomised controlled trial. CRT=cluster randomised trial. SW=stepped wedge. SOC=standard of care. FM=fluorescent microscopy with auramine staining. ZN=direct light microscopy with 
Ziehl-Neelsen staining. NA=not applicable. BMI=body-mass index. NR=not reported. *All trials assessed an intervention group of a single sputum specimen analysed with Xpert MTB/RIF (Generation 3; 
Cepheid, Sunnyvale, CA, USA) in close central laboratories, with the exception of TB-NEAT,15 in which Xpert MTB/RIF was done on site; all trials assessed a SOC group of a single sputum specimen analysed by 
sputum smear microscopy as noted, except XTEND,18 which examined two sputum specimens. †One of five sites (ie, Ifisi Day Clinic in Mbeya, Tanzania) used ZN microscopy. ‡HIV status and CD4 cell count were 
unknown for a certain proportion of participants in some trials. §Denominator used to calculate mortality was the total number of patients for whom the outcome could be assessed at 3 months from 
randomisation. ¶Vital status at 6 months from enrolment was unknown for 48 participants. ||Analysis populations might differ from total population initiating treatment due to missing data or loss to follow-up. 
**Age analysed as a categorical variable.  
Table 1: Baseline participant characteristics
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best estimate being a 12% reduction. Xpert MTB/RIF 
use was not associated with reduced time to tubercu-
losis diagnosis or to com mencement of tuberculosis 
treatment, nor with an increased proportion of 
individuals treated for tuberculosis. We did, however, 
find modest evidence for decreased HIV-specific 
mortality.
Unlike HIV and malaria—other major global causes 
of death and morbidity from infectious disease—there 
is no simple and affordable point-of-care test for 
tuberculosis. In a widely cited decision tree model, Keeler 
and colleagues25 estimated over a decade ago that a new 
rapid tuberculosis diagnostic test with 89% sensitivity 
and 99% specificity, accessible in clinics and hospitals, 
would prevent some 200 000 tuberculosis deaths 
annually, or about 10% of tuberculosis mortality. Invest-
ments in Xpert MTB/RIF have accounted for a substantial 
proportion of global tuberculosis diagnostics spending 
since WHO endorsement in December, 2010, with 
6·9 million Xpert MTB/RIF cartridges procured in the 
public sector of 130 of the 145 countries eligible for 
concessional pricing in 2016 alone.26
A clear effect on patient mortality with programmatic 
use of Xpert MTB/RIF might be difficult to detect for 
several reasons. First, losses within the passive case-
finding cascade during the prediagnostic, or even pre-
treatment,27 periods might not be greatly improved 
by Xpert MTB/RIF. Symptomatic or asymptomatic 
individuals with active tuberculosis who never access 
care or who are not appropriately triaged account for a 
large proportion of the estimated 3·6 million globally 
undetected cases each year, presumably due to 
operational health-system weaknesses. Although not 
included in our analytic population, this group remains 
an important focus for tuberculosis programmes and for 
the implementation of new diagnostic strategies in low-
income and middle-income countries. Basic, trans-
lational, and operational research towards a simple, 
affordable, truly point-of-care test with high analytical 
sensitivity for tuberculosis remains greatly needed. 
Second, the effect of empirical treatment in biasing 
toward the null in diagnostics studies has been 
extensively discussed.20,28,29 The decision to initiate 
treatment in the absence of bacteriological confirmation 
is complex, as it varies by setting,30 patient (eg, highest 
risk patients might be most likely to benefit from early, 
accurate diagnosis, but also more likely to be empirically 
treated), time since test introduction (eg, enthusiasm 
after Xpert MTB/RIF training among South African 
National Department of Health staff might have led to 
baseline imbalances in the XTEND trial18 that favoured 
Xpert MTB/RIF, and empirical treatment has declined 
substantially over time in at least one setting in South 
Africa, possibly an evolving adaptation to Xpert MTB/RIF 
availability),31 and—probably—trial effects.32 Overall, in 
the largest analysed studies15,18,19 and in a 2017 CRT33 of 
centralised versus on-site testing, Xpert MTB/RIF did 
not significantly increase the proportion of patients 
treated for tuberculosis. Finally, insufficient power (ie, 
leading to type 2 error—the risk that a treatment benefit 
will not be shown, even if it exists) is perhaps the most 
common explanation for failure to reach a prespecified 
primary outcome.34 Although post-hoc power curves 
might defy interpre tation,36 to observe a 12% relative 
mortality reduction with use of Xpert MTB/RIF (eg, a 
reduction from 8% to 7% absolute mortality, consistent 
with our reported point estimate) with 90% power would 
require 16 064 people per group, not accounting for 
clustering.
Number of 
adults
OR or HR (95% CI) p value I² p (test of 
homogeneity)
Adults investigated for tuberculosis
6-month mortality risk15,17,18*
Overall 8142 0·88 (0·68–1·14) 0·34 0·0% 0·94
HIV negative 2583 0·83 (0·46–1·5) 0·55 0·0% 0·83
HIV positive 4066 0·83 (0·65–1·05) 0·12 14·8% 0·31
No history of tuberculosis 6519 0·95 (0·76–1·19) 0·67 0·0% 0·58
History of tuberculosis 1623 0·91 (0·51–1·61) 0·74 0·0% 0·39
Time to death
Overall15–18 8561 0·83 (0·65–1·06) 0·13 0·0% 0·75
HIV negative15,17,18 2583 0·81 (0·46–1·41) 0·45 0·0% 0·80
HIV positive15–18 4486† 0·76 (0·60–0·97) 0·03 0·0% 0·47
No history of tuberculosis15–18 6887 0·87 (0·68–1·1) 0·24 0·0% 0·79
History of tuberculosis15–18 1674 0·83 (0·49–1·42) 0·50 0·0% 0·46
3-month mortality risk
Overall15–18 8566 0·91 (0·68–1·20) 0·50 0·0% 0·64
HIV-negative15,17,18 2583 0·74 (0·38–1·45) 0·38 0·0% 0·94
HIV-positive15–18 4490 0·86 (0·66–1·13) 0·29 0·0% 0·46
No history of tuberculosis15–18 6891 1·04 (0·80–1·35) 0·77 0·0% 0·57
History of tuberculosis15–18 1675 0·79 (0·40–1·58) 0·51 0·0% 0·49
Time to tuberculosis diagnosis15,16‡
Overall 1924 1·05 (0·93–1·19) 0·43 47·5% 0·17
HIV positive 1164 0·99 (0·86–1·16) >0·99 25·2% 0·25
Time to tuberculosis treatment
Overall15–18‡ 8208 1·00 (0·75–1·32) 0·99 85·4% <0·0001
HIV negative15,17,18‡ 2482 0·88 (0·60–1·30) 0·52 60·2% 0·08
HIV positive15–18‡ 4251 1·04 (0·76–1·42) 0·80 86·0% <0·0001 
No history of tuberculosis15,16,18‡ 5213 0·9 (0·70–1·17) 0·44 70·0% 0·04
History of tuberculosis15,16,18 1074 0·73 (0·53–0·99) 0·04 0·0% 0·63
Adults investigated for tuberculosis and initiated on treatment
Time to death
Overall15–19 5797 0·67 (0·50–0·90) 0·007 0·0% 0·63
HIV negative15,17–19 2670 0·55 (0·3–1·02) 0·06 0·0% 0·79
HIV positive15–19 1445 0·85 (0·55–1·31) 0·46 18·0% 0·30
All pooled estimates are adjusted for age and gender and are reported with a two-stage analytic approach with fixed 
effects, unless heterogeneity (I²) was high (ie, I²>60%), in which case random effects are primarily reported. Sensitivity 
analyses with random effects regardless of heterogeneity (I²) estimate, additional covariate adjustment, and a one-stage 
analytical approach are reported in the appendix. ORs are reported for 6-month and 3-month mortality risks. HR reported 
for all time-to-event analyses. OR=odds ratio. HR=hazard ratio. *6-month mortality risk was the primary outcome. 
†Five individuals without date of death were excluded. ‡Random effects used to combine study estimates, as I² was large. 
Table 2: Effect of Xpert MTB/RIF on patient outcomes relative to smear microscopy
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Nevertheless, a prespecified secondary subgroup 
analysis did suggest a mortality benefit among HIV-
positive individuals. HIV-associated tuberculosis was one 
of two priority groups (along with individuals investigated 
for drug-resistant tuberculosis) in the initial 2011 WHO 
Xpert MTB/RIF policy statement,2 and high relative 
mortality, particularly among those who are antiretroviral 
treatment naive, increases the statistical power to detect 
an effect in this group. Although a secondary outcome, 
time-to-death analysis included a larger number of indi-
viduals and a more complete covariate adjustment than 
6-month cumulative mortality-risk analysis (our primary 
outcome), leading to increased power. Biological 
plausibility, consistency with diagnostic accuracy,37 with 
modelling data,38 and with the results of a CRT39 of 
tuberculosis screening among adults newly diagnosed 
with HIV in Malawi, reinforce this secondary analysis; 
therefore, we consider this result as overall modest 
evidence that should be replicated.
In a prespecified subgroup analysis, we found that 
individuals tested with Xpert MTB/RIF and who—
regardless of test result—subsequently started tubercu-
losis treatment had lower mortality than those tested with 
sputum smear microscopy. Interpretation of this finding 
is complex, and is a function of our conception of how 
these groups are related and of perceived direction of 
bias. Enhanced analytical sensitivity of Xpert MTB/RIF 
could allow the diagnosis of more individuals at an earlier 
stage in their disease process, or the loss of fewer 
individuals who have a milder disease within the 
diagnostic cascade, accounting for the noted effect (ie, 
lower mortality), than is possible with sputum smear 
microscopy. Alternatively, unmeasured confounding 
from a factor unrelated to diagnostic-test performance 
but differentially distributed among those initiating 
treatment after Xpert MTB/RIF versus sputum smear 
microscopy might account for this apparent association. 
Although arguably the principal mediator of the effect of 
tuberculosis diagnostic test on death and other adverse 
outcomes, tuberculosis treatment is a post-randomisation 
process. Therefore, the assumption of sequential ignor-
ability (ie, that tuberculosis treatment is effectively 
randomly assigned given baseline covariates and the 
randomly allocated diagnostic group) cannot be assumed. 
For this reason, we present these results primarily as 
hypothesis generating.
Our IPD meta-analysis had several limitations. 
First, complete patient-level data were not available 
for CD4-positive T-lymphocyte counts, tuberculosis 
symptoms, and BMI for all studies, precluding full 
adjustment for these key covariates, with tuberculosis 
symptoms and BMI being important covariates in the 
XTEND study.18 Second, we report analysis of our data 
primarily using a two-stage meta-analytic approach, 
because this was required for inclusion of time-phase 
as a covariate for the stepped-wedge trial included in 
this meta-analysis.19 Acknowledging that the one-stage 
approach better accounts for potential risk of ecological 
bias than the two-stage approach,40 no convincing 
evidence exists for the supremacy of one-stage versus 
two-stage approaches. Third, our study results might 
be less applicable to Xpert Ultra, which has a lower 
limit of detection than Xpert MTB/RIF.41 Fourth, 
although the XTEND trial18 was analysed according to a 
cluster-level summary approach in its primary 
publication—as recommended for a small number of 
clusters42—we analysed XTEND herein using random 
effects; we cannot exclude the possibility that this 
analysis might have led to non-robust intervention-
effect estimates for the XTEND study. Finally, our 
analytical population excluded important patient groups 
Figure 2: Kaplan-Meier pooled survival estimates
Shaded areas represent 95% CIs.
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who are likely to draw particular benefit from Xpert 
MTB/RIF, including children and those with rifampicin-
resistant tuberculosis.
In conclusion, in this large multicountry IPD meta-
analysis, we could neither rule in nor rule out a reduction 
in mortality over a 6-month period among outpatients 
tested for tuberculosis with Xpert MTB/RIF rather 
than with sputum smear microscopy. Our finding 
of a potential mortality benefit among HIV-positive 
individuals in our secondary outcome of time to death 
provides justification for trials of novel tuberculosis 
diagnostics in this or other high-risk groups.
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